Investigational drug · Phase 3
siRNA
Also called: ADX-038, ADX-324
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
175
Any phase or sponsor naming "siRNA"
First trial start
2022
Dec 14, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "siRNA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Angioedema
- HAE
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- IC-MPGN
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Hereditary Angioedema (HAE)
- IgAN
- C3G
- Complement-mediated Kidney Disease
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Hereditary angioedema · Rare and genetic disease · Kidney and urology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "siRNA" as an intervention, largest first.
Novartis PharmaceuticalsNovartis (NVS)
NCT05974345 · 204,691 participants · Start Nov 3, 2023 · Primary completion Dec 15, 2023
Drug: Inclisiran sodium; Placebo and 2 more · For: Atherosclerotic Cardiovascular Disease
Sites: Rueil-Malmaison, France
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseasePivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05030428 · 17,004 participants · Start Nov 23, 2021 · Primary completion May 10, 2027
Drug: Inclisiran sodium 300 mg; Placebo · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 989 sites in all
- A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular DiseasePivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT03705234 · 16,124 participants · Start Oct 30, 2018 · Primary completion Oct 2026
Drug: Inclisiran; Placebo · For: Atherosclerotic Cardiovascular Disease
Sites: Boston, Massachusetts; Oxford, United Kingdom
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07181109 · 11,000 participants (planned) · Start Sep 6, 2025 · Primary completion Sep 23, 2030
Drug: Zilebesiran; Placebo · For: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 1,226 sites in all
SanofiSanofi (SNY)
NCT07615179 · 4,545 participants · Start Feb 17, 2025 · Primary completion Sep 30, 2025
Drug: Alirocumab; Comparator: No PCSK9i Therapy (either mAb or siRNA) · For: Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Sites: Bridgewater, New Jersey
SanofiSanofi (SNY)
NCT07734753 · 4,006 participants · Start Jul 15, 2025 · Primary completion May 15, 2026
Drug: Alirocumab; Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents) · For: Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Sites: Amsterdam, Netherlands
- Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-CPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03814187 · 3,275 participants · Start Apr 16, 2019 · Primary completion Feb 13, 2023
Drug: Inclisiran Sodium · For: ASCVD; Elevated Cholesterol; Heterozygous Familial Hypercholesterolemia and 1 more
Sites: Birmingham, Alabama; Foley, Alabama; Huntsville, Alabama · 238 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06858332 · 2,382 participants (planned) · Start Apr 15, 2025 · Primary completion Sep 30, 2027
Drug: Atorvastatin; Simvastatin and 9 more · For: Atherosclerotic Cardiovascular Disease
Sites: Chelyabinsk, Russia; Kaluga, Russia; Kemerovo, Russia · 20 sites in all
- Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein CholesterolPivotal-lookingCompleted
The Medicines CompanyIndustry
NCT03400800 · 1,617 participants · Start Nov 1, 2017 · Primary completion Jul 31, 2019
Drug: Inclisiran Sodium; Placebo · For: ASCVD; Risk Factor, Cardiovascular; Elevated Cholesterol
Sites: Chomutov, Czechia; Uherské Hradiště, Czechia; Berlin, Germany · 70 sites in all
- Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein CholesterolPivotal-lookingCompleted
The Medicines CompanyIndustry
NCT03399370 · 1,561 participants · Start Dec 21, 2017 · Primary completion Sep 10, 2019
Drug: Inclisiran Sodium; Placebo · For: ASCVD; Elevated Cholesterol
Sites: Birmingham, Alabama; Foley, Alabama; Huntsville, Alabama · 145 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A pH/miR-21 dual-responsive multifunctional DNA tetrahedron for targeted tumor imaging and synergistic chemo-gene therapy.
Guo Z, Zhang H, Wang M, et al. · Talanta 2027
- Osteoporosis treatment via programmed delivery of IRF5 siRNA to macrophages in bone tissue combined with ROS scavenging.
Chen Z, Wu J, Zhu Y, et al. · Bioact Mater 2027
- Spontaneous phase separation-driven Janus hydrogel spatiotemporally orchestrates the fibrotic progression for functional tendon regeneration.
Yan W, Zeng W, Zhao J, et al. · Biomaterials 2027
- Cationized gelatin nanosphere-mediated release-controlled RNA interference targeting mTORC1 protects against intervertebral disc degeneration.
Hiranaka Y, Yurube T, Kumagai N, et al. · Bioact Mater 2027
- Chemically tailored lipids mediate solid-phase RNA programming of mineralized microenvironments.
Liu J, Chen Q, Thussananutiyakul J, et al. · Biomaterials 2027
- Salidroside engages HSPA5 and attenuates PERK-eIF2α-ATF4-CHOP signalling in ovariectomy-induced bone loss.
Zhou B, Wang R, Qian T, et al. · J Ethnopharmacol 2027
Also in development for Hereditary Angioedema
- DeucrictibantPHVS416, PHA121Phase 35 trials
Pharvaris Netherlands B.V. · Hereditary Angioedema (HAE), Hereditary Angioedema, Hereditary Angioedema Type I
- KVD900Phase 33 trials
KalVista Pharmaceuticals, Ltd. · Hereditary Angioedema
- NTLA-2002Phase 31 trial
Intellia Therapeutics · Hereditary Angioedema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.